Studying Pathways of Resistance in KRAS-driven Cancers

Up to 250 patients from anywhere in the United States can remotely consent and participate to have plasma drawn locally and submitted to Foundation Medicine, Inc. (FMI), for the FoundationOne® Liquid Biopsy Assay. Patients who have had resistance mechanisms determined through other assays can also consent to share these data. The Investigator(s) will compare mechanisms of acquired resistance across drugs (e.g. sotorasib vs adagrasib) and between tumor types (e.g. NSCLC vs CRC) to determine if different resistance mutations arise in these settings.

NCT Number	NCT05272423
Lead Sponsor	Addario Lung Cancer Medical Institute
Conditions	KRAS P.G12C
Enrollment	58 participants
Start Date	2022-09-08
Primary Completion	2025-12-10 (estimated)
Study Completion	2026-04-06 (estimated)
Updated on ClinicalTrials.gov	2026-08-04